Provided are a
histamine-H3
receptor antagonist; and a preventive and / or a remedy for metabolic
system diseases such as
obesity, diabetes,
hormone secretion disorder, hyperlipemia,
gout,
fatty liver,
circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency,
cardiac infarction, coronary
arteriosclerosis, hypertension,
nephropathy,
sleep disorder and various diseases accompanied by
sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia,
narcolepsy, sleep periodic acromotion disorder,
sleep apnea syndrome,
circadian rhythm disorder,
chronic fatigue syndrome, REM
sleep disorder, senile
insomnia, night worker sleep insanitation, idiopathic
insomnia, repetitive
insomnia, true insomnia,
electrolyte metabolism disorder, and central and
peripheral nervous system diseases such as bulimia,
emotional disorder,
melancholia,
anxiety,
epilepsy,
delirium,
dementia, shinzophrenia,
attention deficit / hyperactivity disorder,
memory disorder, Alzheimer's
disease, Parkinson's
disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia,
epilepsy,
morphine resistance,
narcotic dependency, alcoholic dependency. The
histamine-H3
receptor antagonist comprises a
piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a
nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a
hydrogen atom, a
halogen atom, a linear or branched lower
alkyl group, a lower
alkoxy group, or an acetyl group substituted with 2 or 3
fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.